...
机译:由于肿瘤药物施用途径的潜在成本:荷兰静脉和皮下施用曲妥珠单抗和拉特昔单抗的微观研究
Institute for Medical Technology Assessment;
Institute for Medical Technology Assessment;
Department Oncology Isala Zwolle;
Department of Internal Medicine St. Antonius Hospital Nieuwegein The Netherlands;
Department of Internal Medicine St. Antonius Hospital Nieuwegein The Netherlands;
Hematology;
Medical Oncology Erasmus MC Cancer Institute Rotterdam;
Institute for Medical Technology Assessment;
administration costs; healthcare costs; human epidermal growth factor receptor-2 positive breast cancer; intravenous; microcosting; non-Hodgkin lymphoma; rituximab; societal costs; subcutaneous; trastuzumab;
机译:由于肿瘤药物施用途径的潜在成本:荷兰静脉和皮下施用曲妥珠单抗和拉特昔单抗的微观研究
机译:基于系统性调查,在意大利的17家医院中,皮下注射和静脉注射利妥昔单抗治疗非霍奇金淋巴瘤和曲妥珠单抗治疗乳腺癌的潜在资源和成本节省分析
机译:曲妥珠单抗皮下相对于静脉给药的时间节省:时间和动作研究
机译:胰岛素依赖型糖尿病患者皮下和静脉内胰岛素给药途径的餐后葡萄糖-胰岛素代谢数学模型
机译:向未产妇和多胎劳动妇女服用哌替啶的肌肉内和静脉内途径比较
机译:基于系统调查皮下注射或静脉注射利妥昔单抗治疗非霍奇金淋巴瘤和曲妥珠单抗治疗乳腺癌的潜在资源和成本分析在意大利的17家医院中更正
机译:皮下注射与肿瘤治疗的静脉内给药相比可节省PCN203的资源和成本:利妥昔单抗(Mabthera)和曲妥单抗(Herceptin)的案例研究